UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State
or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS
Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
Telephone Number, Including Area Code: 1-
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On June 25, 2026, the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) established September 24, 2026, as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and July 31, 2026, as the record date for the determination of stockholders entitled to notice of and to vote at the 2026 Annual Meeting. The time, location and additional details for the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting.
As the date of the 2026 Annual Meeting will be more than 30 days after the anniversary of the Company’s 2025 Annual Meeting of Stockholders, the Company is providing notice of the revised deadlines for submission of any qualified stockholder proposal or qualified stockholder nomination in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
For the 2026 Annual Meeting, (a) any stockholder proposal
submitted for inclusion in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act (“Rule 14a-8”)
and (b) any stockholder proposal or director nomination submitted outside of Rule 14a-8, must be received by the Company at its principal
executive offices at the following address, Anavex Life Sciences Corp., 630 5th Avenue, 20th Floor, New York, NY 10111, a reasonable time
before the Company begins to print and send its proxy materials. The Company will consider proposals and director nominations received
on or before July 10, 2026, to be received within a reasonable time before the Company begins to print and send its proxy materials.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | ||
| Date: June 26, 2026 | By: | /s/ Sandra Boenisch |
| Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer | ||